Back to top
more

Omnicell (OMCL)

(Delayed Data from NSDQ)

$42.39 USD

42.39
330,561

+0.88 (2.12%)

Updated Oct 4, 2024 03:59 PM ET

After-Market: $42.36 -0.03 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 252)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Trina Mukherjee headshot

5 Promising Growth Stocks in MedTech to Invest in 2020

by Trina Mukherjee

We have zeroed in on five impressive growth stocks in MedTech on the back of the industry's lucrative prospects.

Invest in These 5 Low Leverage Stocks Before Q4 Earnings

by Zacks Equity Research

Companies displaying high earnings growth along with high leverage ratios should be avoided while making investment decisions. So, investors should select companies with low leverage.

Varian (VAR) Hits a 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Varian (VAR) gains from several positive developments.

Amedisys Gains on Favorable Demography, New Hospice Buyouts

by Zacks Equity Research

Amedisys (AMED) is steadily benefiting from its recent takeovers of hospice care providers, namely RoseRock Healthcare and Compassionate Care Hospice.

Exact Sciences Rides on Cologuard, Eyes Merger Synergies

by Zacks Equity Research

Exact Sciences (EXAS) continues to make a notable progress with its Cologuard business.

Myriad Genetics' GUIDED Clinical Trial Outcome Encouraging

by Zacks Equity Research

The result of this clinical trial is a major stride forward in Myriad Genetics' (MYGN) commitment toward strengthening its portfolio of depressive disorder treatments.

Here's Why You Should Add STERIS (STE) to Portfolio Now

by Zacks Equity Research

Investor confidence is high on STERIS (STE) stock for now, thanks to its solid prospects.

Urmimala Biswas headshot

LabCorp (LH) Grows on Solid Diagnostics Arm Despite PAMA Headwinds

by Urmimala Biswas

LabCorp's (LH) Diagnostics business flourishes organically in terms of both revenues and volumes despite additional price reductions due to Protecting Access to Medicare Act (PAMA).

Here's Why You Should Hold on to Phibro (PAHC) Stock Now

by Zacks Equity Research

Investors can retain Phibro (PAHC) stock for now, thanks to its solid prospects.

Illumina Stock Slips on Pacific Biosciences Deal Termination

by Zacks Equity Research

Per Illumina (ILMN), the lengthy route to achieve regulatory nods for the transaction induces uncertainty about the ultimate outcome of the integration.

Here's Why You Should Hold on to QIAGEN (QGEN) Stock Now

by Zacks Equity Research

Investors can retain QIAGEN (QGEN) stock for now, thanks to its solid prospects.

Here's Why You Should Hold on to Insulet (PODD) Stock Now

by Zacks Equity Research

Investors can retain Insulet (PODD) stock for now on the back of its solid prospects.

Here's Why You Should Hold on to Intersect ENT (XENT) for Now

by Zacks Equity Research

Investors can retain Intersect ENT (XENT) stock for now, courtesy of its solid prospects.

Bio-Rad Gains on New Product Portfolio Despite Currency Woes

by Zacks Equity Research

Bio-Rad's (BIO) new product uptake in the United States is appreciative with the recent 510(k) clearance of the IH-Reader 24.

Syneos Health (SYNH) Hits a 52-Week High: What's Driving It?

by Zacks Equity Research

Syneos Health (SYNH) gains from several positive developments.

Zacks.com featured highlights include: Johnson & Johnson, Gibraltar Industries, Omnicell, MDU Resources and Career Education

by Zacks Equity Research

Zacks.com featured highlights include: Johnson & Johnson, Gibraltar Industries, Omnicell, MDU Resources and Career Education

Here's Why You Should Hold on to Hill-Rom (HRC) Stock Now

by Zacks Equity Research

Investors can retain Hill-Rom (HRC) in their portfolio, courtesy of solid prospects.

    Bet on These 5 Low Leverage Stocks to Invest Judiciously

    by Zacks Equity Research

    Debt level of a company is an important point of consideration while making an investment decision.

    ResMed (RMD) Hits a 52-Week High: What's Driving the Stock?

    by Zacks Equity Research

    ResMed (RMD) gains from impressive performance of its SaaS business.

    Here's Why You Should Add Omnicell to Your Portfolio Now

    by Zacks Equity Research

    Investor confidence in Omnicell (OMCL) is at a high, thanks to solid prospects.

    Omnicell-Huron Sign a Pact for Outcome-Based Expert Services

    by Zacks Equity Research

    Omnicell (OMCL) partners Huron to provide customers with committed expertise.

    Worried About Market Downturn? Buy These Low Leverage Stocks

    by Zacks Equity Research

    Debt is a much cheaper form of financing than equity. Yet the fact that debt carries the burden of interest payments makes it dearer.

    Omnicell (OMCL) Partners With Kit Check to Offer Bluesight

    by Zacks Equity Research

    This partnership will offer Omnicell (OMCL) the state-of-the art technology and medication intelligence needed to ensure accurate delivery of drugs to the right patients.

    Omnicell to Feature Upgrades in Medication Management at ASHP

    by Zacks Equity Research

    Omnicell (OMCL) to showcase innovations in medication management solution portfolio to minimize human errors by care providers.

    Zacks.com featured highlights include: Manulife, Gibraltar, Omnicell, SolarEdge and Career Education

    by Zacks Equity Research

    Zacks.com featured highlights include: Manulife, Gibraltar, Omnicell, SolarEdge and Career Education